These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study. Vesikari T; Saez-Llorens X; Blazevic V; Lopez P; Lopez E; Masuda T; Mendelman PM; Liu M; Sherwood J; Baehner F; Borkowski A Vaccine; 2022 Jun; 40(26):3588-3596. PubMed ID: 35595661 [TBL] [Abstract][Full Text] [Related]
5. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140 [TBL] [Abstract][Full Text] [Related]
6. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828 [TBL] [Abstract][Full Text] [Related]
10. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain. Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863 [TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. Leroux-Roels G; Cramer JP; Mendelman PM; Sherwood J; Clemens R; Aerssens A; De Coster I; Borkowski A; Baehner F; Van Damme P J Infect Dis; 2018 Jan; 217(4):597-607. PubMed ID: 29140444 [TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Treanor J; Sherwood J; Cramer JP; Le Cam Bouveret N; Lin S; Baehner F; Borkowski A; Vaccine; 2020 Aug; 38(36):5842-5850. PubMed ID: 32563606 [TBL] [Abstract][Full Text] [Related]
13. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642 [TBL] [Abstract][Full Text] [Related]
14. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera. Malm M; Tamminen K; Vesikari T; Blazevic V Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization. Malm M; Vesikari T; Blazevic V Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058 [TBL] [Abstract][Full Text] [Related]
16. An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. Atmar RL; Cramer JP; Baehner F; Han C; Borkowski A; Mendelman PM J Infect Dis; 2019 Jan; 219(3):410-414. PubMed ID: 30203081 [TBL] [Abstract][Full Text] [Related]
17. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes. Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474 [TBL] [Abstract][Full Text] [Related]
18. Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant. Tamminen K; Malm M; Vesikari T; Blazevic V Viruses; 2019 Jan; 11(2):. PubMed ID: 30678195 [TBL] [Abstract][Full Text] [Related]